Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 10/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3255545 | 0.89 | KEAP1 (0.47) | HCRTR2HCRTR1PKMPTGER1MAPT | |
| SCHEMBL8272874 | 0.89 | HPGD (0.49) | HCRTR2HCRTR1PKMPTGER1MAPT | |
| SCHEMBL14107584 | 0.86 | PTGER1 (0.50) | PTGER1MAPTTP53TSHR | |
| SCHEMBL8272224 | 0.83 | HPGD (0.48) | HCRTR2HCRTR1PKMPTGER1MAPT | |
| SCHEMBL3256115 | 0.83 | MAPT (0.39) | HCRTR2HCRTR1PKMPTGER1MAPT | |
| SCHEMBL3252639 | 0.83 | MAPT (0.42) | HCRTR2HCRTR1PKMPTGER1MAPT | |
| SCHEMBL8273865 | 0.82 | HPGD (0.46) | PKMPTGER1MAPTTP53 | |
| SCHEMBL3244402 | 0.82 | MAPT (0.41) | ALDH1A1PKMPTGER1MAPTTP53 | |
| SCHEMBL14107583 | 0.81 | HPGD (0.50) | HCRTR2HCRTR1PKMMAPTTP53 | |
| SCHEMBL4143155 | 0.81 | KMT2A (0.39) | PKMMAPTTP53TSHROXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776347-B1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI AVENTIS (FR) | 2010-05-26 | — | — | EP | disclosed |
| US-7396958-B2 | Sulphonamide derivatives, their preparation and their therapeutic application | SANOFI AVENTIS (FR) | 2008-07-08 | — | — | US | disclosed |
| US-20070185136-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| EP-1776347-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Sanofi-Aventis (FR) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006024779-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185136-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | HCRTR2, GIPR, SSTR2 | HCRTR2 1/4885HCRTR1 6/4885ALDH1A1 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.